|
[Related PubMed/MEDLINE] Total Number of Papers: 64
|
|
|
[Entries Per Page]
|
per page
|
|
Page Control
|
|
Page: of |
|
|
|
No. |
Year |
Title |
Co-occurring Abbreviation |
1 |
2020 |
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. |
ET, HC |
2 |
2020 |
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. |
B-ALL, CAR-T cells, CI, CRS, EFS, GVHD, ICANS |
3 |
2020 |
Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients. |
ALL, allo-HSCT, DLIs, MRD, OS, RFS |
4 |
2020 |
Outpatient low toxic regimen with bortezomib in relapsed/refractory acute lymphoblastic leukemia in pediatrics and AYA patients: Single-center Mexican experience. |
BZ |
5 |
2020 |
What is the role of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia? |
allo-HCT, AML, GVHD, NRM, RCT |
6 |
2019 |
A Rare Case of Primary Central Nervous System Lymphoma in an Adolescent Female Treated with High-Dose Methotrexate and Rituximab-Based Chemoimmunotherapy and Consolidation Whole Brain Radiotherapy. |
HD-MTX, MRI, PCNSL, WBRT |
7 |
2019 |
Impact of Leukemia Stem Cells Phenotype Expression on Response to Induction Therapy in Acute Myeloid Leukemia Patients. |
FAB, LSCs |
8 |
2019 |
Low-dose cyclosporine for active lupus nephritis: a dose titration approach. |
AR, LN |
9 |
2019 |
The benefit of surveillance imaging for paediatric cerebellar pilocytic astrocytoma. |
iMRI, PA |
10 |
2019 |
[Analysis of clinical characteristics, treatment response rate and survival of 77 myelodysplastic syndrome patients with del (5q) syndrome]. |
ACA, CCyR, CyR, LEN, MDS, OS |
11 |
2018 |
A rare case of paediatric primary central nervous system lymphoma treated with high-dose methotrexate and rituximab-based chemoimmunotherapy and whole brain radiotherapy followed by tumour bed boost with three-dimensional conformal radiation technique. |
DLBCL, HD-MTX, MRI, PCNSL, WBRT |
12 |
2018 |
Consolidation Radiation Therapy for Patients With Advanced Hodgkin Lymphoma in Complete Metabolic Response According to PET-CT or Gallium Imaging. |
CHT, CI, CMT, HL, HR, PET-CT, PFS, RT |
13 |
2018 |
How much primary tumor metabolic volume reduction is required to improve outcome in stage III NSCLC after chemoradiotherapy? A single-centre experience. |
CRT, MS, NSCLC, PT-MV |
14 |
2018 |
Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. |
allo-HCT, AML, CIR, HR, MRD, NGS, VAF |
15 |
2018 |
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens. |
CHC, DAAs, IFN, MC, RBV |
16 |
2018 |
Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis. |
CI, eGFR, ESRD, HR, LN, SDI |
17 |
2018 |
Testing for minimal residual disease in adults with acute lymphoblastic leukemia in Europe: a clinician survey. |
ALL, MRD |
18 |
2017 |
Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. |
CC, LN |
19 |
2016 |
Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy. |
AML, CCR, DFS, NPM1, SWOG |
20 |
2016 |
Posttreatment FDG-PET-CT response is predictive of tumor progression and survival in anal carcinoma. |
CT, FDG PET-CT, OS, PFS |
21 |
2015 |
A Case Report of Long-Term Survival following Hepatic Arterial Infusion of L-Folinic Acid Modulated 5-Fluorouracil Combined with Intravenous Irinotecan and Cetuximab Followed by Hepatectomy in a Patient with Initially Unresectable Colorectal Liver Metastases. |
HAI |
22 |
2015 |
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. |
OS |
23 |
2015 |
Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial. |
HR |
24 |
2015 |
Total radiation dose and overall treatment time are predictive for tumor sterilization in cervical carcinoma treated with chemoradiation and pulsed-dose-rate brachytherapy. |
CTV, HR-CTV, RD |
25 |
2014 |
Allogeneic mesenchymal stem cell transplantation for lupus nephritis patients refractory to conventional therapy. |
BILAG, GFR, LN, MSCs, MSCT, PR, SLEDAI |
26 |
2014 |
Clofarabine/cyclophosphamide for debulking before stem cell transplantation. |
HSCT, pts |
27 |
2014 |
Surgical treatment of neuroblastoma: twenty-three years of experience at a single institution. |
NB, NMYCA, OS |
28 |
2013 |
Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. |
AL, BD, Mel, PR, SCT |
29 |
2013 |
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. |
CAPTEM, NETs, PR, SD, TMZ |
30 |
2013 |
Dynamic contrast-enhanced CT to assess metabolic response in patients with advanced non-small cell lung cancer and stable disease after chemotherapy or chemoradiotherapy. |
DCE, DCE-CT, NR, NSCLC, PET, RECIST, RER |
31 |
2013 |
Significant efficacy of 2-chlorodeoxyadenosine{+/-} rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. |
PR, SLVL/SMZL, SMZL |
32 |
2012 |
Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. |
AL, HDM |
33 |
2012 |
Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization. |
AFP, HCC, TACE |
34 |
2012 |
Minimal residual disease in acute myeloid leukemia: coming of age. |
AML, MRD |
35 |
2012 |
Response rate and clinical outcome of HCC after first and repeated cTACE performed "on demand". |
cTACE |
36 |
2011 |
Solitary skeletal osteosarcoma recurrence. Findings from the Cooperative Osteosarcoma Study Group. |
COSS, EFS, OS |
37 |
2010 |
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). |
SMZL |
38 |
2010 |
[Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis]. |
CTD, VGPR |
39 |
2009 |
Early lymphocyte recovery after allogeneic hematopoietic SCT is associated with significant GVL effect in pediatric ALL but not acute myelogenous leukemia-Update study. |
HSCT |
40 |
2009 |
The effectiveness and safety of mycophenolate mofetil in lupus nephritis. |
LN, MMF |
41 |
2007 |
Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells. |
AML, APL, ATRA, CMR, LSC, RFS |
42 |
2007 |
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. |
HDM/SCT |
43 |
2007 |
Transurethral Resection of Bladder Tumor (TUR-BT) then Concomitant Radiation and Cisplatin Followed by Adjuvant Gemcitabine and Cisplatin in Muscle Invasive Transitional Cell Carcinoma (TCC) of the Urinary Bladder. |
CCRT, PFS, RC, TCC, TURBT |
44 |
2007 |
Usefulness of MRI volumetric evaluation in patients with squamous cell cancer of the head and neck treated with neoadjuvant chemotherapy. |
PR, SSCHN |
45 |
2005 |
Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. |
CCR, MALT, RD |
46 |
2005 |
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. |
CI, MALT, MALT |
47 |
2005 |
Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). |
COSS, OS |
48 |
2005 |
Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. |
AML, BR |
49 |
2005 |
Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. |
FLC, HDM/SCT, IFE |
50 |
2005 |
[Acute myeloid leukemia with pulmonary manifestation]. |
--- |
51 |
2004 |
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. |
GR, MDS, RA |
52 |
2003 |
Predictors of long-term immunological outcome in rebounding patients on protease inhibitor-based HAART after initial successful virologic suppression: implications for timing to switch. |
AUC, NRTI, PI, REB, REB |
53 |
2003 |
Tumor response to induction chemoradiation: influence on survival after esophagectomy. |
RT |
54 |
2000 |
Detection of acute promyelocytic leukemia (APL) cells intermediately differentiated by all-trans retinoic acid in the cerebrospinal fluid: central nervous system involvement in APL. |
APL, ATRA |
55 |
2000 |
Monitoring of minimal residual disease in patients with MLL-AF6-positive acute myeloid leukaemia by reverse transcriptase polymerase chain reaction. |
AML, BMT, FISH, RT-PCR |
56 |
2000 |
Nodal T cell blast crisis in chronic myeloid leukemia. |
BC, CML |
57 |
1999 |
Real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21)-positive AML patients. |
AML |
58 |
1998 |
Matched unrelated donor marrow transplantation in patients with advanced acute leukemia. |
AL, ALL, AML, GVHD, HLA, MUD |
59 |
1995 |
Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia. |
APL, ATRA, RT-PCR |
60 |
1995 |
Kinetics of minimal residual disease during induction/consolidation therapy in standard-risk adult B-lineage acute lymphoblastic leukemia. |
ALL, BM, CDR3, GMALL, IgH, MRD, PCR, TCR gamma |
61 |
1995 |
[Rearrangement of the alpha RAR and pml genes in promyelocytic leukemia]. |
APL |
62 |
1994 |
Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. |
EGFR, MR, PCNA, PR |
63 |
1994 |
Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haemopoietic malignancies. |
BMT, CT, FISH, metaphase-FISH |
64 |
1992 |
Shedding of CD9 antigen by bone marrow cells from patients with acute lymphoblastic leukaemia. |
BM |
|